121 related articles for article (PubMed ID: 15724932)
1. [A case of effective use of alemtuzumab in a male patient with T-cell lymphoma].
Sokolov AH; Parovichnikova EN; Isaev VG; Ustinova EN; Shavlokhov VS; Atopkov VA; Model SV; Tsyba NN; Kaplanskaia IB; Kliasova GA; Aleksanian MZh; Vishnevskaia ES; Togonidze DK; Mirzoian EE; Savchenko VG
Ter Arkh; 2004; 76(12):73-5. PubMed ID: 15724932
[No Abstract] [Full Text] [Related]
2. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
Miles SA; McGratten M
J Clin Oncol; 2005 Jan; 23(1):247-8. PubMed ID: 15625386
[No Abstract] [Full Text] [Related]
3. Prolonged remission in a case of Richter's transformation of B-cell chronic lymphocytic leukaemia following adoptive immunotherapy.
Milojković D; Aldouri M; Pagliuca A; Mufti GJ; Devereux S
Bone Marrow Transplant; 2006 Sep; 38(6):461-2. PubMed ID: 16951694
[No Abstract] [Full Text] [Related]
4. A male with primary breast lymphoma.
Miura Y; Nishizawa M; Kaneko H; Watanabe M; Tsudo M
Am J Hematol; 2009 Mar; 84(3):191-2. PubMed ID: 18932237
[No Abstract] [Full Text] [Related]
5. Indolent lymphoma: can rituximab resolve the watch-and-wait debate?
Ross E
J Natl Cancer Inst; 2010 Feb; 102(4):220-1. PubMed ID: 20145214
[No Abstract] [Full Text] [Related]
6. [Antibody therapy in hematology and oncology - part 1].
Kneba M; Schrader C; Köhne H
Med Klin (Munich); 2008 Dec; 103(12):843-59. PubMed ID: 19099214
[No Abstract] [Full Text] [Related]
7. Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Williams KM; Higman MA; Chen AR; Schwartz CL; Wharam M; Colombani P; Arceci RJ
Pediatr Blood Cancer; 2008 Mar; 50(3):667-70. PubMed ID: 17318876
[TBL] [Abstract][Full Text] [Related]
8. Bilateral primary renal lymphoma.
James TC; Shaikh H; Escuadro L; Villano JL
Br J Haematol; 2008 Oct; 143(1):1. PubMed ID: 18513283
[No Abstract] [Full Text] [Related]
9. A long-lasting third complete remission after second autologous transplant followed by maintenance treatment with rituximab in a patient with diffuse large cell non-Hodgkin's lymphoma.
Ataergin S; Arpaci F; Beyzadeoglu M; Safali M; Ozet A
Am J Hematol; 2006 Dec; 81(12):986-7. PubMed ID: 16886214
[No Abstract] [Full Text] [Related]
10. A case of CD20-positive peripheral T-cell lymphoma treated with rituximab and multiagent chemotherapy.
Kamata M; Sugaya M; Miyagaki T; Sonoda K; Ichimura Y; Mitsui H; Sato S; Kamikubo Y; Kurokawa M
Int J Dermatol; 2014 Jan; 53(1):e24-6. PubMed ID: 23452101
[No Abstract] [Full Text] [Related]
11. CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review.
Kircher SM; Gurbuxani S; Smith SM
J Gastrointest Cancer; 2007; 38(1):19-23. PubMed ID: 19065718
[TBL] [Abstract][Full Text] [Related]
12. Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin.
Ravandi F; Faderl S
Leuk Res; 2006 Jan; 30(1):103-5. PubMed ID: 15979704
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large B-cell lymphomas, leg type, in elderly patients.
Guyot A; Ortonne N; Valeyrie-Allanore L; Bagot M
Arch Dermatol; 2010 Jan; 146(1):89-91. PubMed ID: 20083704
[No Abstract] [Full Text] [Related]
14. Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine.
Jaeger G; Bauer F; Brezinschek R; Beham-Schmid C; Mannhalter C; Neumeister P
Ann Oncol; 2008 May; 19(5):1025-6. PubMed ID: 18375525
[No Abstract] [Full Text] [Related]
15. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.
Cooles FA; Jackson GH; Menon G; Isaacs JD
Rheumatology (Oxford); 2011 Apr; 50(4):810-2. PubMed ID: 21208978
[No Abstract] [Full Text] [Related]
16. [Immunotherapy with monoclonal antibody of malignant lymphoma].
Ogura M
Nihon Rinsho; 2007 Jan; 65 Suppl 1():545-60. PubMed ID: 17474462
[No Abstract] [Full Text] [Related]
17. Rituximab plus CHOP for diffuse large-B-cell lymphoma.
Akhtar S; Maghfoor I
N Engl J Med; 2002 Jun; 346(23):1830-1; author reply 1830-1. PubMed ID: 12050349
[No Abstract] [Full Text] [Related]
18. CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review.
Kircher SM; Gurbuxani S; Smith SM
J Gastrointest Cancer; 2007; 38(1):59-62. PubMed ID: 19065726
[TBL] [Abstract][Full Text] [Related]
19. Treatment with alemtuzumab in a case of refractory primary cutaneous CD30-negative CD8-positive cytotoxic large T-cell lymphoma.
Gutierrez A; Rodriguez J; Ramos R; Gines J; Sampol A; Galmes B; Besalduch J
Eur J Haematol; 2004 May; 72(5):377-8. PubMed ID: 15059077
[No Abstract] [Full Text] [Related]
20. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.
Kluin-Nelemans HC; van Marwijk Kooy M; Lugtenburg PJ; van Putten WLJ; Luten M; Oudejans J; van Imhoff GW
Ann Oncol; 2011 Jul; 22(7):1595-1600. PubMed ID: 21212158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
